Precision BioSciences, Inc. (NASDAQ:DTIL - Free Report) - HC Wainwright lifted their FY2027 earnings per share (EPS) estimates for Precision BioSciences in a research report issued on Tuesday, November 5th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of $0.20 for the year, up from their prior forecast of $0.19. HC Wainwright currently has a "Buy" rating and a $60.00 target price on the stock. The consensus estimate for Precision BioSciences' current full-year earnings is $0.82 per share. HC Wainwright also issued estimates for Precision BioSciences' FY2028 earnings at $0.40 EPS.
Precision BioSciences Price Performance
DTIL stock traded down $0.06 during midday trading on Wednesday, reaching $8.40. 84,484 shares of the company were exchanged, compared to its average volume of 77,467. Precision BioSciences has a one year low of $7.97 and a one year high of $19.43. The firm has a market capitalization of $60.77 million, a price-to-earnings ratio of 140.00 and a beta of 1.71. The business has a 50-day moving average price of $9.31 and a two-hundred day moving average price of $10.05.
Institutional Trading of Precision BioSciences
A hedge fund recently bought a new stake in Precision BioSciences stock. Janus Henderson Group PLC acquired a new position in shares of Precision BioSciences, Inc. (NASDAQ:DTIL - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 573,052 shares of the company's stock, valued at approximately $7,739,000. Janus Henderson Group PLC owned 8.29% of Precision BioSciences as of its most recent SEC filing. Institutional investors and hedge funds own 37.99% of the company's stock.
Precision BioSciences Company Profile
(
Get Free Report)
Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.
Read More
Before you consider Precision BioSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Precision BioSciences wasn't on the list.
While Precision BioSciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
